Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Harpoon Therapeutics Begins Trial of Novel Immuno-Oncololgy Drug in Patients with Metastatic Castration-Resistant Prostate Cancer
Harpoon Therapeutics Begins Trial of Novel Immuno-Oncololgy Drug in Patients with Metastatic Castration-Resistant Prostate Cancer
Harpoon Therapeutics Begins Trial of Novel Immuno-Oncololgy Drug in Patients with Metastatic Castration-Resistant Prostate Cancer
Submitted by
admin
on August 6, 2018 - 9:46am
Source:
CP Wire
News Tags:
Harpoon Therapeutics
HPN424
metastatic castration-resistant prostate cancer
Headline:
Harpoon Therapeutics Begins Trial of Novel Immuno-Oncololgy Drug in Patients with Metastatic Castration-Resistant Prostate Cancer
snippet:
Clinical data expected in 2019
HPN424 is designed as an ‘off-the-shelf’ T cell therapy
HPN424 serum half-life of 80 hours supporting once-weekly administration
Do Not Allow Advertisers to Use My Personal information
